XPeng or NIO: Which Chinese EV Stock Looks Stronger Now?
NIO's current lineup spans sedans, SUVs and coupes, including models like ES6, EC6, ES7, ES8, EC7, ET5, ET5T, ET7, ET9, EP9. In late March 2025, NIO began deliveries of its luxury flagship sedan, ET9. Beyond its core lineup, NIO is expanding its reach through two sub-brands. ONVO, its mainstream mass-market brand, debuted L60, which has been well-received by consumers. Deliveries of its second vehicle, L90, are expected to begin in the third quarter of 2025, followed by a third model in the fourth quarter. Meanwhile, Firefly—NIO's high-end compact EV brand—unveiled its first model in April 2025.
XPeng also has a diversified lineup. It also bets big on intelligence-driven vehicles. Its offerings include G9 (a mid- to large-sized SUV), P7i (a sporty sedan), G6 (a sleek coupe SUV), P7+ (a family sedan), MONA M03 (a value-priced sedan) and X9 (a seven-seat MPV). This month, XPeng introduced its latest model, G7—a crossover positioned between G6 and G9. Within 46 minutes of opening pre-orders, G7 attracted over 10,000 reservations, signaling strong market interest. G7 is also the first model equipped with XPeng's in-house Turing AI chip, which reportedly delivers triple the computing power of standard smart driving chips.
While NIO offers a broader brand presence across price tiers, XPeng's focus on intelligent driving and diverse vehicle styles, along with the early buzz surrounding its G7 launch, underscores its tech-driven strategy. This product innovation focus could help XPeng gain ground in an increasingly crowded market.
XPeng has delivered a knockout performance on the delivery front. In 2024, it delivered 190,068 vehicles — a 34.2% increase year over year. The momentum surged in 2025, with 94,008 vehicles delivered in the first quarter alone, marking a jaw-dropping 331% jump from the prior-year period. That momentum continues, with 35,045 vehicles delivered in April (up 273% year over year) and 33,525 in May (up 230%). XPeng expects second-quarter deliveries in the band of 102,000-108,000, representing year-over-year growth of 238%-257%.
NIO, though growing steadily, is now trailing in volumes. It delivered 221,970 vehicles in 2024 — higher than XPeng's total — but the story has changed in 2025. NIO sold 42,094 units in the first quarter of 2025 — less than half of XPeng's quarterly tally. April deliveries rose 53% year over year to 23,900 units, while May deliveries climbed a modest 13.1% to 23,231 units. For second-quarter 2025, NIO projects deliveries in the range of 72,000-75,000 vehicles, implying a rise of 25.5-30.7% year over year.
In terms of growth and volume, XPeng is clearly in the driver's seat.
XPeng delivered strong top-line growth in the last reported quarter, with revenues surging 141.5% year over year to $2.18 billion. Its net loss narrowed significantly to $90 million, reflecting improving operational efficiency. Vehicle margin improved to 10.5% from 5.5% a year ago.
NIO generated $1.66 billion in revenues in the last reported quarter, up 20.8% year over year. However, it remains deeply in the red, with a net loss of $930 million — a 30% increase from the prior-year period. Its vehicle margin was 10.2%, slightly below XPeng's but up from 9.2% in the prior-year quarter.
While both firms are still unprofitable, XPeng is seeing stronger revenue growth and a healthier trend in narrowing losses, giving it a modest edge on the financial front.
Both NIO and XPeng are spending money on advanced technologies, but their approaches differ. NIO's standout innovation is its battery swap tech, with over 3,400 stations deployed globally. It's also advancing smart driving with its NIO World Model (NWM), part of its NADArch 2.0 architecture. NWM enables real-time decision-making from raw sensor data and is now live on Banyan-based vehicles.
XPeng, meanwhile, is doubling down on full-stack intelligence. Its AI Hawkeye Visual Solution and XOS 5.4 operating system showcase an integrated approach to smart driving. XPeng is also thinking beyond the road—developing humanoid robots, flying cars and in-house AI chips. While some of these projects may seem far-fetched, they reflect XPeng's bold vision for the future of mobility.
For now, XPeng's ambition and breadth of innovation give it a clear edge.
While NIO stock has struggled so far in 2025, XPeng shares have seen a solid upswing—likely fueled by investor excitement around its advancements in autonomous driving, robotics and AI.
Image Source: Zacks Investment Research
Both stocks trade at relatively low forward price-to-sales ratios versus their historical averages. However, XPeng's forward P/S ratio of 1.25 is notably higher than NIO's 0.42.
Image Source: Zacks Investment Research
Despite both companies being unprofitable, the market appears to be rewarding XPeng's bold tech narrative and improving financials, while remaining cautious on NIO amid continued losses and margin pressure.
The Zacks Consensus Estimate for XPEV's 2025 bottom line suggests 66.7% year-over-year growth, while the 2026 estimate implies a 207% jump from 2025 projected levels. See how estimates for XPeng have been revised in the past 90 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for NIO's 2025 and 2026 bottom line implies a year-over-year improvement of 31% and 59%, respectively. See how estimates for NIO have been revised in the past 90 days.
Image Source: Zacks Investment Research
At this point, neither NIO nor XPeng is a screaming buy. Both carry a Zacks Rank #3 (Hold), which suggests investors should stay cautious in the short term. That said, if we have to pick one over the other, it would be XPeng. It's growing faster, cutting its losses, and generating more excitement around its tech, especially in autonomous driving and AI.
NIO still has some strong cards to play, like its battery swap network and broader brand strategy. But NIO hasn't turned those advantages into the same kind of growth and margin progress we're seeing from XPeng. For investors looking to tap into China's EV growth story, XPeng looks like the more promising one now.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NIO Inc. (NIO) : Free Stock Analysis Report
XPeng Inc. Sponsored ADR (XPEV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Asian Penny Stocks To Watch In July 2025
As global markets celebrate positive developments, such as the U.S. and China signing a new trade deal, Asian indices have also shown resilience and potential for growth. Penny stocks may be an older term, but they continue to represent intriguing opportunities in the investment landscape, particularly within smaller or newer companies. By identifying those with strong financial health and clear growth prospects, investors can uncover potential gems that offer both stability and upside in today's market conditions. Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.29 HK$813.93M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$2.04 HK$3.53B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.27 HK$1.89B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.435 SGD176.3M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.05 HK$1.75B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.25 SGD8.86B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.182 SGD36.26M ★★★★★★ BRC Asia (SGX:BEC) SGD3.12 SGD855.97M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.64 HK$53.16B ★★★★★★ United Energy Group (SEHK:467) HK$0.52 HK$13.44B ★★★★★★ Click here to see the full list of 1,001 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: HuBei NengTer Technology Co., Ltd operates an ecommerce platform focused on the supply chain of plastic raw materials in China, with a market cap of CN¥8.82 billion. Operations: Currently, there are no reported revenue segments available for this company. Market Cap: CN¥8.82B HuBei NengTer Technology Ltd., with a market cap of CN¥8.82 billion, recently reported first-quarter sales of CN¥2,877.27 million and net income of CN¥215.9 million, reflecting an improvement from the previous year's figures despite a decline in sales compared to last year. The company has completed a share buyback worth CN¥329.98 million, enhancing shareholder value without significant dilution over the past year. While unprofitable with increasing losses over five years, it maintains sufficient cash runway for more than three years and holds more cash than its total debt, indicating financial stability amidst volatility concerns. Unlock comprehensive insights into our analysis of HuBei NengTer TechnologyLtd stock in this financial health report. Examine HuBei NengTer TechnologyLtd's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.99 billion. Operations: No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd. Market Cap: CN¥11.99B Tianjin Chase Sun Pharmaceutical Co., Ltd, with a market cap of CN¥11.99 billion, reported first-quarter sales of CN¥1.39 billion and net income of CN¥60.33 million, showing slight growth from the previous year despite declining sales figures. The company's short-term assets significantly exceed its liabilities, and it holds more cash than debt, indicating a strong liquidity position. However, profit margins have decreased to 0.4% from 6.6% last year, raising concerns about profitability sustainability amid negative earnings growth over the past year and low return on equity at 0.3%. Recent board changes may influence strategic direction moving forward. Dive into the specifics of Tianjin Chase Sun PharmaceuticalLtd here with our thorough balance sheet health report. Assess Tianjin Chase Sun PharmaceuticalLtd's future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hunan Er-Kang Pharmaceutical Co., Ltd is engaged in the manufacturing and sale of APIs, finished drug products, and pharmaceutical excipients both in China and internationally, with a market cap of CN¥6.91 billion. Operations: Hunan Er-Kang Pharmaceutical Co., Ltd has not reported specific revenue segments. Market Cap: CN¥6.91B Hunan Er-Kang Pharmaceutical, with a market cap of CN¥6.91 billion, has shown mixed financial performance. Despite a decline in annual revenue from CN¥1.78 billion to CN¥1.14 billion and an increased net loss of CN¥373.37 million for 2024, the company reported improved first-quarter sales of CN¥353.55 million and net income of CN¥28.11 million in 2025 compared to the previous year. The company's short-term assets exceed both its long-term and short-term liabilities, indicating strong liquidity, yet its negative return on equity and high share price volatility highlight ongoing profitability challenges amid increased debt levels over time. Navigate through the intricacies of Hunan Er-Kang Pharmaceutical with our comprehensive balance sheet health report here. Review our historical performance report to gain insights into Hunan Er-Kang Pharmaceutical's track record. Navigate through the entire inventory of 1,001 Asian Penny Stocks here. Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:002102 SZSE:300026 and SZSE:300267. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati


Bloomberg
33 minutes ago
- Bloomberg
Bloomberg Businessweek Daily: Amazon's Chief Technologist
Amazon's robotics unit has just deployed its one millionth robot, building on its position as the world's largest manufacturer and operator of mobile robotics. This milestone robot was recently delivered to a fulfillment center in Japan, joining a global network that now spans more than 300 facilities worldwide. Tye Brady, Chief Technologist for Amazon's expansive robotics unit, explains how new AI technology will make the world's largest fleet of industrial mobile robots smarter and more efficient.
Yahoo
43 minutes ago
- Yahoo
High Growth Tech Stocks In Asia Baiwang And Two More
As global markets experience a rally with indices like the S&P 500 and Nasdaq Composite hitting all-time highs, Asian tech stocks are drawing attention due to their potential for high growth amidst easing trade tensions and positive economic signals. In this environment, a good stock often demonstrates robust innovation capabilities and adaptability to market changes, making it well-positioned to capitalize on technological advancements and economic shifts. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.78% 30.32% ★★★★★★ Fositek 28.54% 35.14% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ PharmaResearch 24.91% 26.60% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ CARsgen Therapeutics Holdings 81.05% 87.21% ★★★★★★ JNTC 55.45% 94.52% ★★★★★★ Click here to see the full list of 485 stocks from our Asian High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Baiwang Co., Ltd. offers enterprise digitalization solutions via the Baiwang Cloud platform in China, with a market capitalization of HK$9.59 billion. Operations: Baiwang Co., Ltd. generates revenue primarily from its Internet Software & Services segment, which contributes CN¥659.21 million to its financials. Baiwang, amid recent executive and auditor changes, demonstrates a dynamic corporate environment that could influence its strategic direction. Despite currently being unprofitable, the company is poised for significant growth with revenue expected to increase by 18.7% annually, outpacing the Hong Kong market's 8.2%. This growth trajectory is supported by an impressive forecast of earnings expansion at 112.91% per year. However, it's crucial to note Baiwang's current lack of profitability and negative free cash flow status which may pose challenges in sustaining this rapid growth without effective capital management strategies in place. Navigate through the intricacies of Baiwang with our comprehensive health report here. Gain insights into Baiwang's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Sun Create Electronics Co., Ltd is involved in the research and development, design, manufacture, and marketing of radar and security systems with a market capitalization of CN¥8.43 billion. Operations: The company generates revenue primarily from the electronic industry, with reported earnings of CN¥1.56 billion. The focus on radar and security systems forms the core of its business operations. Sun Create Electronics, despite its recent unprofitability, is on a promising trajectory with an expected annual revenue growth of 33.8%, significantly outpacing the Chinese market's 12.4%. This growth is underpinned by a robust forecast in earnings expansion at an impressive rate of 143.3% annually, positioning it well above average market growth projections. The firm's commitment to innovation is evident from its R&D spending trends, which are crucial for maintaining competitive advantage in the fast-evolving tech sector. However, investors should be cautious about its high volatility in share price and recent net losses which decreased from CNY 553.23 million to CNY 245.88 million year-over-year, reflecting some improvement but still posing challenges for future stability and profitability. Delve into the full analysis health report here for a deeper understanding of Sun Create Electronics. Review our historical performance report to gain insights into Sun Create Electronics''s past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog active pharmaceutical ingredients and injections in China with a market capitalization of approximately CN¥33.89 billion. Operations: The company generates revenue primarily from the development, production, and sale of insulin and related products, amounting to approximately CN¥3.47 billion. Gan & Lee Pharmaceuticals has showcased a robust trajectory with its earnings and revenue growth significantly outpacing the industry. Over the past year, earnings surged by 114.7%, dwarfing the biotech sector's decline of 17.7%. This performance is supported by an aggressive R&D investment strategy, crucial in propelling future innovations and maintaining a competitive edge in high-growth markets. The company also demonstrated strong financial health with a net income jump from CNY 96 million to CNY 311.92 million in the latest quarter, reflecting a strategic alignment towards lucrative market segments. Despite these strengths, its projected annual revenue growth of 20% suggests more moderate future expansion compared to some peers, warranting careful monitoring of market position and investment viability moving forward. Get an in-depth perspective on Gan & Lee Pharmaceuticals' performance by reading our health report here. Assess Gan & Lee Pharmaceuticals' past performance with our detailed historical performance reports. Dive into all 485 of the Asian High Growth Tech and AI Stocks we have identified here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:6657 SHSE:600990 and SHSE:603087. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@